During the past decade, Azienda Ospedaliero-Universitaria "Mater Domini" conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 21 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 14 clinical trials were completed. i.e. 34.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria "Mater Domini"" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "University Magna Graecia" with 6 trials sponsored, "Shire" with 5 trials sponsored and "Amgen" with 5 trials sponsored. Other sponsors include 49 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliero-Universitaria "Mater Domini"" #1 collaborator was "Azienda Ospedaliera Universitaria Mater Domini, Catanzaro" with 3 trials as a collaborator, "Azienda Sanitaria Provinciale Di Catanzaro" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliero-Universitaria "Mater Domini"" are "Ulcerative Colitis" (11 trials), "Breast Cancer" (5 trials), "Acute Respiratory Failure" (4 trials), "Atrial Fibrillation" (4 trials) and "Crohn Disease" (4 trials). Many other conditions were trialed in "Azienda Ospedaliero-Universitaria "Mater Domini"" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliero-Universitaria "Mater Domini"" are "Drug" (60 trials), "Other" (19 trials), "Device" (7 trials), "Procedure" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Paclitaxel" (5 trials), "Trastuzumab" (5 trials), "Ontamalimab" (4 trials) and "Tirzepatide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliero-Universitaria "Mater Domini"" are 84 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are 44 active trials in "Azienda Ospedaliero-Universitaria "Mater Domini"". 3 are not yet recruiting, 23 are recruiting, 17 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 32 completed trials in Azienda Ospedaliero-Universitaria "Mater Domini", undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliero-Universitaria "Mater Domini", 4 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 9 trials that are defined as “Not Applicable".

Azienda Ospedaliero-Universitaria "Mater Domini" has several departments that took part in Clinical trials: "U.O. Fisiopatologia Digestiva" - 6 trials, "A.O. Ospedale Mater Domini, Oncoematologia Università Magna Grecia" - 2 trials, "AOU Policlinico "Mater Domini" UOC di Medicina interna" - 2 trials